Mr. Pascoe joined Apricus in March of 2013 following the merger of Somaxon Pharmaceuticals with Pernix. At Somaxon Mr. Pascoe was the Chief Executive Officer since August 2008 and was responsible for the FDA approval of Somaxon’s lead drug Silenor®. Prior to Somaxon, Mr. Pascoe was with ARIAD Pharmaceuticals, Inc., a specialty pharmaceutical company where he was most recently Senior Vice President and Chief Operating Officer.

Prior to joining ARIAD in 2005, Mr. Pascoe held a series of senior management roles at King Pharmaceuticals, Inc., a specialty pharmaceutical company, including Senior Vice President positions in both marketing and sales, as well as Vice President positions in both international sales and marketing and hospital sales. Prior to King, Mr. Pascoe was in the commercial groups at Medco Research, Inc. (which was acquired by King), COR Therapeutics, Inc., B. Braun Interventional and The BOC Group. Mr. Pascoe is a member of the board of directors of KemPharm, Inc., Cohera Medical, Inc., and the Corporate Directors Forum (CDF).

Mr. Pascoe served as a Commissioned Officer with the U.S. Army 24th Infantry Division, following his graduation from the United States Military Academy at West Point where he received a B.S degree in Leadership.

Mr. Martin, a certified public accountant, has over 25 years of financial leadership, with significant expertise in growing public companies in a variety of industries, including the life sciences. Since 2008, Mr. Martin served as Senior Vice President and Chief Financial Officer of BakBone Software, a publicly-traded software company. Mr. Martin also served as Interim CEO over the final 10 months with BakBone and through the successful sale of the company that was completed in January of 2011. From 2005 to 2007, Mr. Martin served as Chief Financial Officer of Stratagene Corporation, a publicly-traded company specializing in the development, manufacture and marketing of specialized research and clinical diagnostic products. Mr. Martin’s experience also includes the position of Controller with publicly-traded Gen-Probe Incorporated, a life sciences company, as well as 10 years with the public accounting firm of Deloitte & Touche.

Mr. Martin holds a B.S. in Accounting from San Diego State University. In 2011, Mr. Martin was awarded the San Diego Business Journal’s “CFO of the Year Award” for Medium Public Companies. He is also the former President and a member of the Board of Directors of the Financial Executives International San Diego Chapter.

Mr. Cox is the Company’s Vice President, Commercial Development with a primary focus on supporting the launches of Vitaros^® in Europe and Canada. Mr. Cox has previously served as Vice President of Business Development, Corporate Development and Investor Relations for the Company and since December 2009. Prior to that time, Mr. Cox was the President and a member of the Board of Directors of Bio-Quant which was acquired by Apricus. He has broad experience in finance and strategic business planning for companies in the areas of Healthcare, Life Science, Technology and Resources. Mr. Cox has served as an Officer and/or Director of several early-stage companies.

Mr. Cox holds a Master of Science in Management from the Warrington College of Business Administration at the University of Florida, and his Certified Licensing Professional (CLP) certification from the Licensing Executives Society.

.

Dr. Meier-Davis joined Apricus as Vice President of Safety in February 2012, directing the pharmacovigilance and nonclinical/clinical safety activities for the company. Additionally, she currently serves as project leader for the Femprox® development program and manages clinical development. Dr. Meier-Davis has more than 16 years of wide-ranging experience in the pharmaceutical industry having actively participated in transdermal, anti-infective, Alzheimer’s disease, chemotherapy and cardiovascular drug development. Previously, Dr. Meier-Davis was the Director of Nonclinical at Teikoku Pharma USA and Fibrogen and held Senior Scientist positions at Theravance and Alza. Dr. Meier-Davis has authored many nonclinical and clinical sections for both US and EU submissions, several peer-reviewed journal articles and holds five patents.

Dr. Meier-Davis received her Doctor of Veterinary Medicine (DVM) degree from the University of Wisconsin at Madison and her Ph.D. in molecular pharmacology from the Stanford University School of Medicine. Dr. Meier-Davis is board-certified in toxicology from the American Board of Toxicology (DABT) and certified in regulatory affairs (RAC) for both medical devices and pharmaceuticals.

Dr. Martin has over 20 years of research and development experience in the fields of antibacterial, inflammation, oncology, antiviral, antifungal, cardiovascular and metabolic diseases as well as sexual dysfunction. Dr. Martin oversees the chemistry, manufacturing and supply chain activities for the company, which he joined as Vice President of Chemistry in March 2010. Previously, Dr. Martin was the Senior Director of Chemistry, founding partner and investor of RetroVirox. Dr. Martin was also with X-Ceptor therapeutics as the Director of Chemistry, which was acquired by Exelixis in 2004 for their valuable metabolic disease programs.

Dr. Martin obtained his Ph.D. from the University of Toronto and pursued postdoctoral studies at The Scripps Research Institute in San Diego. He has over 30 patent applications, 20 of which have been granted in the United States and several publications in peer-reviewed journals.

Mr. Morton brings to Apricus a successful track record in business development in specialty pharmaceuticals, most recently serving as the Executive Director of Business Development at Auxilium Pharmaceuticals Inc., where he successfully led their efforts to build a pipeline of men’s health products. Prior to Auxilium Pharmaceuticals, Mr. Morton served in business development and marketing roles at King Pharmaceuticals, attaining the position of Senior Director, Commercial Development.

Mr. Morton received his M.B.A. degree from the Babcock Graduate School of Management at Wake Forest University and his B.A. degree in biology from Bucknell University.